Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022

Rhea-AI Summary

IVERIC Bio (ISEE) announced the presentation of new post-hoc analyses from the GATHER1 Phase 3 trial for Zimura® (avacincaptad pegol) at the Angiogenesis, Exudation, and Degeneration 2022 meeting on February 11-12, 2022. The analyses aim to assess the effectiveness of Zimura in slowing Geographic Atrophy (GA) progression related to Age-related Macular Degeneration (AMD). Presenters include experts from Duke Eye Center and Cleveland Clinic. IVERIC Bio plans to release more details during the presentations and will share slides on its website.

Positive

• Presentation of new post-hoc analyses from the GATHER1 trial highlights the potential of Zimura to slow GA progression.
• Engagement in a significant medical conference provides visibility for IVERIC Bio's research advancements.

Negative

• None.

NEW YORK--(BUSINESS WIRE)-- IVERIC Bio, Inc. (Nasdaq: ISEE) announced today that new post-hoc analyses from the GATHER1 Zimura^® (avacincaptad pegol) Phase 3 clinical trial for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration will be presented at the upcoming Angiogenesis, Exudation, and Degeneration 2022 meeting taking place virtually on February 11 and 12, 2022.

“We are excited to have these new analyses of the GATHER1 clinical trial presented at the upcoming Angiogenesis meeting,” stated Pravin U. Dugel, MD, President of Iveric Bio. “While the analyses are considered exploratory we believe they further highlight the potential for Zimura to slow the progression of disease and preserve foveal anatomy in patients with GA secondary to AMD.”

The analyses will be presented in oral sessions. Details of the presentations are as follows:

Presentation Title: Evaluation of GA Growth Parameters and Impact on Foveal Progression: Post Hoc Analysis of the GATHER1 Trial

• Presenter: Glenn J. Jaffe, MD, Director, Duke Reading Center Chief, Retina Division, Duke Eye Center, Robert Machemer Professor of Ophthalmology
• Date / Time: Friday, February 11, 2022, 11:00am (ET)

Presentation Title: Novel OCT Findings Regarding “Nascent GA at Risk” and Directionality of GA Progression in the GATHER1 Trial

• Presenter: Peter K. Kaiser, MD, Chaney Family Endowed Chair for Ophthalmology Research Professor of Ophthalmology Cleveland Clinic Lerner College of Medicine.
• Date / Time: Friday, February 11, 2022, 11:10am (ET)

Iveric Bio will issue a press release relating to the results of the post-hoc analyses and make the slides available on the Company’s website on the Events and Presentation page at the start of the presentations.

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, the Company’s forward looking statements include statements about its expectations regarding its development and regulatory strategy for Zimura, its plans for additional indications, such as intermediate AMD, that the Company may pursue for the development of Zimura, the potential utility of Zimura and the clinical meaningfulness of clinical trial results. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the progress and success of research and development programs and clinical trials, and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220205005019/en/

Investor Contact:

Iveric Bio

Kathy Galante, 212-845-8231

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com



or



Media Contact:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

Source: IVERIC Bio, Inc.

FAQ

What is the focus of IVERIC Bio's GATHER1 Phase 3 trial?

The GATHER1 Phase 3 trial focuses on evaluating Zimura® (avacincaptad pegol) for treating Geographic Atrophy caused by Age-related Macular Degeneration.

When will the results of the GATHER1 trial analyses be presented?

The results will be presented at the Angiogenesis, Exudation, and Degeneration 2022 meeting on February 11-12, 2022.

What does the post-hoc analysis from the GATHER1 trial aim to assess?

The post-hoc analysis aims to evaluate the efficacy of Zimura in slowing the progression of Geographic Atrophy.

Who will present the findings from the GATHER1 trial?

The findings will be presented by experts including Glenn J. Jaffe, MD, and Peter K. Kaiser, MD.

What is the significance of the GATHER1 trial for IVERIC Bio's stock (ISEE)?

The GATHER1 trial's results may impact IVERIC Bio's market perception and stock performance, depending on the efficacy demonstrated by Zimura in the analyses.